Skip to main content

Lumakras FDA Approval History

Last updated by Judith Stewart, BPharm on June 2, 2021.

FDA Approved: Yes (First approved May 28, 2021)
Brand name: Lumakras
Generic name: sotorasib
Dosage form: Tablets
Company: Amgen Inc.
Treatment for: Non Small Cell Lung Cancer

Lumakras (sotorasib) is a KRASG12C inhibitor for the treatment of patients with KRAS G12C-mutated locally advanced or metastatic non- small cell lung cancer (NSCLC), following at least one prior systemic therapy.